Jun 28 |
You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
|
Jun 27 |
Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study
|
Jun 26 |
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
|
Jun 14 |
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
|
Jun 6 |
Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?
|
May 30 |
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
|
May 14 |
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
|
May 13 |
15 Best ARK Stocks To Buy Now
|
May 9 |
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
|
May 9 |
Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
|